Sunday, August 19, 2018
News

Cipla launches of Hepcvir-L for Chronic Hepatitis C Genotype 1 Patients

   SocialTwist Tell-a-Friend    Print this Page   COMMENT

Mumbai | Monday, Dec 21 2015 IST
Pharma major, Cipla Ltd, today announced thelaunch of generic drug Ledipasvir-Sofosbuvir in India under thebrand name Hepcvir-L. Hepcvir-L is the first once-a-day, fixed-doseoral combination therapy that has been approved for chronichepatitis C genotype 1 patients.The introduction of the Ledipasvir-Sofosbuvir fixed-dose oralcombination thereby provides a new interferon and ribavirin-freetreatment option to patients and is a powerful weapon to fightagainst genotype 1 hepatitis C virus.Commenting on the launch of Ledipasvir-Sofosbuvir, Mr. SubhanuSaxena, MD & Global CEO, Cipla Limited said, ''Cipla has alwaystried to provide best-in-class affordable medicines to patients andthe launch of Ledipasvir-Sofosbuvir is a further step to facilitatethe optimal treatment for patients suffering from genotype 1hepatitis C virus.''UNI JS NV AW1235

-- (UNI) -- C-1-DL0169-498266.Xml

Loading...
 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
INDIA WORLD ASIA
Tejaswi demands expulsion of senior JD (...
Telangana govt sends 20 tonnes of milk p...
Illustrations on vintage postcards, lett...
Kerala diaspora in Middle East helps flo...
Photojournalist missing from MP capital...
Asian Games 2018: Bajrang Punia storms i...
More...    
 
 Top Stories
ED to move HC against appellate tri... 
Back series GDP data not official e... 
Swimmers Nataraj, Prakash finish fi... 
802 pilgrims pay obeisance at Amarn... 
J&K Govt bans posting of teachers i... 
Hameed Karra expresses concern over... 
One arrested in ATM cheating case i... 
DGP reviews security arrangements f...